GlassScriptPhysician profile
Kabekode D Verma
NPI 1477763563
$11,955.99
in general payments reported to CMS, 2019-2025
31 companies · $3,153 in 2025
The $3,153 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $882 · 2021: $1,183 · 2022: $1,997 · 2023: $2,327 · 2024: $1,750 · 2025: $3,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,152 · Education: $78.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,152.14 |
| Education | $78.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,463.28 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,845.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $794.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $763.47 | 2019-2025 | |
| Pfizer INC. | $710.21 | 2019-2025 | |
| Optinose US, INC. | $654.24 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $619.03 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $572.62 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Kaleo, INC. | $454.55 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $439.37 | 2025 | Neffy |
| Grifols USA, LLC | $433.30 | 2019-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $431.59 | 2019-2023 | Airduo Digihaler |
| Genentech USA, INC. | $268.24 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $263.92 | 2023-2025 | Ayvakit |
| Incyte Corporation | $216.04 | 2022-2023 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $170.84 | 2022 | |
| Galderma Laboratories, L.P. | $143.23 | 2025 | Nemluvio |
| Octapharma USA, INC. | $113.99 | 2021-2023 | Octagam Immune Globulin (Human) |
| Abbvie INC. | $99.05 | 2024 | |
| Aerin Medical INC. | $87.79 | 2022 | |
| Amgen INC. | $75.97 | 2022-2023 | Tezspire |
| Csl Behring | $51.29 | 2024 | Hizentra |
| Organon LLC | $48.20 | 2025 | |
| Hikma Pharmaceuticals USA | $44.66 | 2022-2024 | Ryaltris |
| Alk-Abello, INC | $38.68 | 2019-2023 | Odactra |
| Biocryst US Sales Co., LLC | $35.42 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $32.13 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2022 | |
| Hospira, INC. | $22.41 | 2025 | |
| Pharming Healthcare, INC. | $18.96 | 2023 | Ruconest |
| Phadia US INC. | $14.19 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kabekode Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.